AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

Axsome Therapeutics (AXSM) incurred an adjusted loss of $1.22 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of$1.26. The company had incurred a loss of $1.44 per share in the year-ago quarter.Axsome’s total revenues surged 62$121.5 million in the first quarter, beating the Zacks Consensus Estimate of $119 million. The year-over-year increase in revenues can be attributed to strong sales of Auvelity (AXS-05). (Find the latest EPS estimates a ...